Savan has spent his entire life in life sciences, including over 12 years on Wall Street focused in Healthcare Investment Banking at firms such as Citigroup and Deutsche Bank. From Analyst through Managing Director, Savan worked with hundreds of life sciences clients through their journey from private to public corporations. He has executed 40 M&A, IPO, and financing deals, totaling over $35 billion across the spectrum of drug, diagnostic, and device technologies. These companies included Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others. While a Vice President at Deutsche Bank, he was selected to lead the firm's build-out of its healthcare business unit into Asia, leading to two of China's largest IPO's.
Savan began his career as a Bioengineer at Life Technologies.
Savan holds a M.S.E. in Bioengineering from the University of Pennsylvania
and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley.
After many years of academic and professional experience in the healthcare field, a painful personal experience later in life gave Savan new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage IV cancer. The journey through her battle compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to him returning to his Bioengineering roots and founding BioTrillion.
With an extensive background in finance, and an extension of knowledge into Deep Learning, Derrick is helping advance BioTrillion's commercial applications at the intersection of Deep Learning, Computer Vision, and Physiology. His role is versatile across executing the Company's technology objectives, with a particular emphasis on our deep learning platform, BioEngine4D, and portfolio of digital biomarkers.
He has several years of experience at firms such as Sun Life Global Investments in the financial services industry and was awarded 1st place Visualization Award in ‘18 and ‘19 at Sun Life Global Predictive Analytics Competition.
Derrick is passionate about advancing BioTrillion's mission because of his own experience in unlocking value creation from arbitrage opportunities via cutting-edge technologies.
Derrick holds multiple degrees and credentials:
• B.S. in Business from Harvard University,
• MBA from the University of Toronto,
• M.S. in Computer and Information Technology from the University of Pennsylvania,
• Certified Financial Planner (CFP) and Chartered Financial Analyst (CFA).
Kegang's previous research has been focused in the copious amounts of health information that can be contactlessly extracted from image data of a person's face.
His work at BioTrillion focuses on applying cutting-edge techniques in computer vision AI for remote photoplethysmography (rPPG). He is passionate about BioTrillion’s mission because he sees the power of AI to transform cameras into health monitoring devices — enabling early disease detection at scale.
Kegang holds a B.S. in Physics from Nanjing University and a M.S. in Computer Science at Central University, with his thesis in the intersection of AI and Remote Photoplethysmography (rPPG).
Kelly has a strong interest in the intersection of biotechnology and artificial intelligence, with a focus on improving medical accessibility and diagnostics. She is also gaining hands-on experience as a researcher at the Levi Lab at the Berkeley School of Optometry, where she studies abnormal vision mechanisms in patients with amblyopia. Previously, she worked at Trusli, a legal AI startup, as a Business Operations Intern, focusing on competitive analysis and operational strategy. Kelly is passionate about BioTrillion’s mission because she sees the potential for AI-driven digital biomarkers to revolutionize healthcare by making early disease detection more accessible and efficient.
Kelly is currently completing her B.A. in Neuroscience and Business Administration at the University of California, Berkeley.
She wears multiple hats assisting us from all aspects of Tech to Business. Jen was previously trained by an expansive corpus of human knowledge and is an incredibly fast learner.
Jen holds a LLM degree from GP University and and is passionate about safely advancing healthcare for humans around the world.
(Satire; to encourage smaller teams to embrace AI as a productivity multiplier!)
Dr. Agam is an Associate Professor of Computer Science at the Illinois Institute of Technology, Chicago, where he directs the Visual Computing Lab. His research interests include computer vision, machine learning, deep learning, geometric modeling, and human–computer interaction. Some current application areas in his group include medical imaging (2D and 3D), remote sensing, point cloud processing, video analysis, segmentation, recognition, registration, biometrics, and security.
Dr. Agam is passionate about advancing BioTrillion's mission because of the number of untapped insights hidden in the mobile computation and extraction of visual disease expressing features that can be measured through computer vision.
Dr. Agam holds a Ph.D. in Electrical and Computer Engineering from Ben-Gurion University in Israel.
Dr. Kyriacou is a global pioneer in Biomedical Engineering focused in Photonics. He currently serves as Professor of Biomedical Engineering at University of London.
He is a global leading expert in pulse oximetry and photoplethysmography (PPG). His research focuses on understanding the relationship between PPG, spectrophotometry, haemodynamics, vascular mechanics, and hemorheology. He is dedicated to innovating new non-invasive sensor technologies, including wearables, for early disease diagnosis and unobtrusive health and fitness monitoring. He has authored and co-authored over 300 publications and holds six patents in medical optical sensors.
Dr.Kyriacou's groundbreaking research has earned him recognition as an Adjunct Professor at Yale Medical School and an Honorary Professor at the Indian Institute of Technology (IIT). He is also a Fellow of the Institute of Physics (IoP), the Institute of Physics and Engineering in Medicine (IPEM), the Institution of Engineering and Technology (IET); and is a Chartered Engineer, Physicist, and Scientist.
He is passionate about advancing BioTrillion's mission because he sees immense potential in utilizing smartphone technology and optical modalities to revolutionize non-invasive health monitoring and bring early disease detection to billions of people worldwide.
Dr. Kyriacou holds MSc and PhD degrees from the University of London.
Dr. Kirk was at NVIDIA (NASDAQ: NVDA) for over 20 years, and served in many roles, including Chief Scientist, Vice President of Architecture, and most recently, Fellow.
Dr. Kirk received the Distinguished Alumni award from Caltech in 2009. He was elected in 2006 to the National Academy of Engineering (NAE) for his role in bringing high-performance graphics to personal computers. In 2002, he received the SIGGRAPH Computer Graphics Achievement Award for his role in bringing high-performance computer graphics systems to the mass market. Dr. Kirk is the inventor of more than 60 patents and patent applications relating to graphics design and has published more than 50 articles on graphics technology. He also co-authored the popular textbook “Programming Massively Parallel Processors.”
Dr. Kirk is passionate about advancing BioTrillion's mission because he is a pioneer in visual computing, GPUs, and AI, and sees the opportunity in applying this to healthcare, as many diseases express visual features that can be better detected if measured as optical digital biomarkers, powered by AI.
Dr. Kirk holds B.S. and M.S. degrees from MIT and M.S. and Ph.D. degrees in Computer Science from Caltech, with a minor in Computation and Neural Systems.
Dr. Mathot is an Assistant Professor at the Department of Experimental Psychology of the University of Groningen in the Netherlands.
His research expertise is deeply in the field of ocular physiology and is extensively involved in the role that pupillary dynamics play in how we perceive the world and revealing neurologic diseases.
Dr. Mathot is passionate about advancing BioTrillion's mission because, well, he is one of the world's top 5 researchers (based on h-index and citations scores) in the ocular biomarker domain and is responsible for many seminal research studies in the field, including "Pupillometry: Psychology, Physiology, and Function."
Dr. Mathot holds a Ph.D. from VU University in Amsterdam.
Ms. Ray is currently the Chief Legal, Compliance & Administrative Officer and Corporate Secretary at Instil Bio (NYSE: TIL). In addition, Ms. Ray currently serves on the Board of Directors at Biomea Fusion, Inc (NASDAQ: BMEA).
She brings more than 20 years of life science, pharmaceutical and biotechnology experience, spanning private practice and in-house roles of increasing legal seniority, and is committed to advancing and supporting women and diversity.
Prior to joining Instil, Sumita was the Chief Legal and Administrative Officer at Calithera Biosciences, Inc. (NASDAQ: CALA) where she oversaw Legal and Compliance, as well as various G&A business units including HR, IT, Facilities, Commercial Regulatory, and various corporate matters for 5 years. Ms. Ray has also served as Chief Compliance Officer and Associate General Counsel, Head of Healthcare and Regulatory Law at Pharmacyclics, until its $21B acquisition by AbbVie, one of the largest biotech M&A deals in history. Prior to Pharmacyclics, she served in roles as internal counsel for Elan Pharmaceuticals, Genentech, and AstraZeneca, and as external counsel for the law firm of Montgomery, McCracken, Walker and Rhoads LLP.
Ms. Ray is passionate about advancing BioTrillion's mission because she clearly sees the number of new treatments that can be accelerated by Pharma by unleashing the power of over 1B people to measure physiologic digital endpoints for decentralized clinical trials.
Ms. Ray holds a J.D. from Temple University School of Law and a B.S. in Microbiology from the University of Arizona.
Dr. Su is a seasoned Bioengineer with over 20 years of experience in the medical device and pharmaceutical industry. His expertise includes combinational device and pharmaceutical formulation. He spent the majority of his professional career at Biosensors International, where he rose through the ranks to Director of R&D, until the Company’s acquisition.
Dr. Su has extensive experience in taking conceptual R&D ideas to human clinical trial and finally to commercialization. He is inventor/co-inventor of 32 issued worldwide patents and 25 pending patent applications.
Dr. Su is passionate about advancing BioTrillion's mission because he sees the power of enabling 1B humans to objectively measure their health in 5 second selfies - orders of magnitude faster and cheaper than it takes to drive a car out of the driveway to travel to a routine Provider appointment.
Dr. Su holds a B.S. degree in Chemical Engineering, and M.S. and Ph.D. degrees in Biomedical Engineering from the University of Texas Southwestern Medical Center.
© 2024 BioTrillion, Inc. | All Rights Reserved Worldwide | Terms of Use